Due to the acquisition of Serono, the significance of royalty income in the income statement has increased considerably. Therefore, royalty income is now presented together with sales under total revenues. In 2007, royalty income totaled €282.0 million (2006: € 19.5 million) and mainly included Serono royalty income from the products Avonex® (Biogen Idec), Humira® (Abbott), Enbrel® (Amgen) and Puregon® (Schering-Plough). The previous year’s figure primarily included income from the pharmaceutical active ingredients bisoprolol and metformin.
